Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MedImmune Inc. deal

MEDI (Gaithersburg, Md.) acquired worldwide exclusive rights to commercialize T10B9, an anti-T cell murine monoclonal antibody developed at the University of Kentucky.

In a 76-patient,

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE